Suppr超能文献

头孢孟多治疗b型流感嗜血杆菌引起的脑膜炎失败。

Failure of cefamandole in treatment of meningitis due to Haemophilus influenzae type b.

作者信息

Steinberg E A, Overturf G D, Wilkins J, Baraff L J, Streng J M, Leedom J M

出版信息

J Infect Dis. 1978 May;137 Suppl:S180-S189. doi: 10.1093/infdis/137.supplement.s180.

Abstract

The in vitro activity of cefamandole was determined against 58 isolates of Haemophilus influenzae type b; 47 were beta-lactamase-negative (ampicillin-susceptible), and 11 produced beta-lactamase (ampicillin-resistant). Ampicillin-susceptible strains were susceptible to cefamandole with a median minimal bactericidal concentration (MBC) of 0.4 microgram/ml. Ampicillin-resistant strains had a median MBC of 0.8 microgram/ml. Prior studies have documented these concentrations of cefamandole in cerebrospinal fluid in the presence of inflamed meninges. Three children with meningitis due to H. influenzae type b were treated with cefamandole (200 mg/kg per day), including one child with disease due to an ampicillin-resistant strain. All patients showed clinical improvement during therapy. However, sterility of the cerebrospinal fluid was never achieved in two patients during 72--96 hr of therapy with cefamandole. The third patient relapsed with a recurrence of positive cultures during the seventh day of cefamandole therapy. Therefore, cefamandole does not appear to be a useful agent for treatment of meningitis due to H. influenzae type b irrespective of in vitro susceptibility or evidence of penetration into the cerebrospinal fluid.

摘要

测定了头孢孟多对58株b型流感嗜血杆菌的体外活性;其中47株为β-内酰胺酶阴性(对氨苄西林敏感),11株产生β-内酰胺酶(对氨苄西林耐药)。对氨苄西林敏感的菌株对头孢孟多敏感,中位最低杀菌浓度(MBC)为0.4微克/毫升。对氨苄西林耐药的菌株中位MBC为0.8微克/毫升。先前的研究已记录在脑膜发炎时脑脊液中头孢孟多的这些浓度。3例b型流感嗜血杆菌脑膜炎患儿接受了头孢孟多治疗(每日200毫克/千克),其中1例患儿感染的是对氨苄西林耐药的菌株。所有患者在治疗期间临床症状均有改善。然而,在使用头孢孟多治疗72 - 96小时期间,有2例患者脑脊液从未实现无菌。第3例患者在头孢孟多治疗第7天培养结果再次呈阳性,出现复发。因此,无论体外药敏情况或脑脊液中药物渗透证据如何,头孢孟多似乎都不是治疗b型流感嗜血杆菌脑膜炎的有效药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验